ArteraAI Breast FDA Clearance — First Digital Pathology AI Breast Cancer Risk Stratification. NCCN 2026 Official Inclusion
AI officially enters breast cancer diagnosis·treatment decisions. Artera 2026.5.6 FDA Clearance — ArteraAI Breast = first FDA-cleared digital pathology AI breast cancer risk stratification. NCCN 2026 guidelines include AI 5-year risk ≥1.7% threshold for clinical decision framework.
Key Announcement
ArteraAI Breast FDA Clearance: Approval 2026.5.6, indication HR+/HER2- early-stage breast cancer, first FDA-cleared digital pathology AI risk stratification, slide analysis → 5-year recurrence risk prediction
NCCN 2026 Guidelines: AI 5-year risk ≥1.7% threshold, adjuvant chemotherapy decision support, precision decision framework entry, clinical universalization begins
Digital Pathology AI
Digital Pathology: Tissue slide digital scan, high-resolution imaging, AI·deep learning analysis, pathologist·AI collaboration
ArteraAI Breast specialization: HR+/HER2- early-stage (most common), hormone receptor positive + HER2 negative, adjuvant chemo decision support, recurrence risk prediction
NCCN Guidelines Meaning
NCCN: Authoritative US cancer guidelines, Korea·global clinical influence, clinician standard
AI threshold 1.7%: AI 5-yr recurrence <1.7% = chemo possibly avoidable, ≥1.7% = chemo considered, decision support standardization
Existing Risk Stratification
Oncotype DX: 21-gene test, Recurrence Score (RS), $3,000~$5,000, Korea partial insurance
MammaPrint: 70-gene test, low·high risk, $3,000~$5,000
ArteraAI differentiation: Slide-based (existing material), instant results, ↓ cost (expected), multi-country applicable
L73 Next Step Dimension - 3rd Axis
40 pillars + L72 NEJM AI bias (shadow) + L73 ArteraAI Breast (light - FDA official) = AI medicine verification·establishment·clinical entry next step. Shadow awareness + light establishment = balance.
Phase Plan
Now (2026.5): HR+/HER2- early-stage, NCCN inclusion, FDA Cleared
Expansion: ArteraAI Prostate (existing) + ArteraAI Breast (L73) + lung·colon·ovarian (planned)
Korean Implications
Korean breast cancer risk stratification: Oncotype DX partial (insurance), MammaPrint partial, AI digital pathology partial adoption starting (university hospitals)
ArteraAI Breast adoption: FDA → Korean MFDS 1~2 yr, 2027 expected, $500~$1,500 expected, university hospital·cancer centers priority
Korean Breast Cancer
Korean women: #1 female cancer, 30,000+ new annually, mean diagnosis age 49, 5~10 yr survivors 500K+, 70% HR+ (ArteraAI target)
ArteraAI meaning Korea: HR+/HER2- most common, precision chemo decisions, ↓ overtreatment·↑ QoL
40 Pillars + Breast Cancer - L73 Total
40 pillars breast cancer related: L63 elacestrant ESR1 (precision drug), L66 ASCO GLP-1 breast cancer prevention, L67 Veppanu PROTAC (degradation), L69 ASCO BWEL (weight·QoL), L73 ArteraAI Breast (AI diagnosis) = diagnosis → prevention → treatment → AI integrated multi-axis.
Automation Bias (L72) vs AI Diagnosis (L73)
L72 NEJM AI bias: LLM diagnostic reasoning -14%p pulled, 80%+ clinical reasoning failure, AI = adjunct, no solo decision
L73 ArteraAI: Specialized diagnostic tool (not LLM), FDA Cleared = clinically validated, NCCN guidelines = standard, doctor + AI collaboration
Meaning: General LLM = limited, specialized AI = clinical entry possible, verification·balance = core
FAQ
Q. AI replaces doctor diagnosis? A. Adjunct tool. Doctor final decision. NCCN guideline also specifies AI = adjunct.
Q. ArteraAI vs Oncotype DX? A. Oncotype = genetic. ArteraAI = slide AI. Complementary use.
Q. Korea availability? A. 2027 expected. University hospital·cancer centers priority. Insurance TBD.
Q. Skip chemotherapy possible? A. ArteraAI risk <1.7% = possible (doctor decision). Patient-comprehensive evaluation.
Q. Other cancers? A. Artera platform prostate existing. Lung·colon·ovarian expansion planned.
Conclusion
ArteraAI Breast FDA Clearance + NCCN guideline = AI diagnosis clinical decision framework entry. HR+/HER2- early-stage 70% female applicable. L73 = 50 pillars + next step dimension (AI diagnosis 3rd axis). Korea 2027 expected. L72 automation bias awareness + L73 specialized AI validation = balanced AI medicine.